```
      (FILE 'HOME' ENTERED AT 17:14:50 ON 19 JAN 2007)

      FILE 'REGISTRY' ENTERED AT 17:15:27 ON 19 JAN 2007
L1              STRUCTURE UPLOADED
L2           50 SEA SSS SAM L1
                DISPLAY L2 1-50

      FILE 'REGISTRY' ENTERED AT 17:18:06 ON 19 JAN 2007
L3              STRUCTURE UPLOADED
L4           50 SEA SSS SAM L3
                DISPLAY L4 1-5 ALL

      FILE 'REGISTRY' ENTERED AT 17:25:33 ON 19 JAN 2007
                SET LINE 250
                SET DETAIL OFF
                E "HYDROXYGLYCINAMIDE"/CN 25
                E "HYDROXYLGLYCINAMIDE"/CN 25
                E "HYDROXY LGLYCINE AMIDE"/CN 25
                E "HYDROXY GLYCINE AMIDE"/CN 25
                E "GLYCINE AMIDE"/CN 25
                SET NOTICE 1000 SEARCH
L5            1 SEA ABB=ON  PLU=ON  "GLYCINE AMIDE"/CN
                SET NOTICE 1 DISPLAY
                SET LINE LOGIN
                SET DETAIL LOGIN
                DIS L5 1 SQIDE
                SET NOTICE LOGIN DISPLAY
                SET NOTICE LOGIN SEARCH
L6           79 SEA ABB=ON  PLU=ON  C2H6N2O2/MF
                DISPLAY L6 1-79 ALL


      FILE HOME

      FILE REGISTRY
      Property values tagged with IC are from the ZIC/VINITI data file
      provided by InfoChem.

      STRUCTURE FILE UPDATES:   18 JAN 2007  HIGHEST RN 917867-30-2
      DICTIONARY FILE UPDATES:  18 JAN 2007  HIGHEST RN 917867-30-2

      New CAS Information Use Policies, enter HELP USAGETERMS for details.

      TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006

        Please note that search-term pricing does apply when
        conducting SmartSELECT searches.

      REGISTRY includes numerically searchable data for experimental and
      predicted properties as well as tags indicating availability of
      experimental property data in the original document.  For information
      on property searching in REGISTRY, refer to:

      http://www.cas.org/ONLINE/UG/regprops.html

=> display l6 9 all

L6   ANSWER 9 OF 79  REGISTRY  COPYRIGHT 2007 ACS on STN
RN   748135-32-2  REGISTRY
ED   Entered STN:  20 Sep 2004
CN   Acetamide, 2-amino-2-hydroxy- (9CI)  (CA INDEX NAME)
MF   C2 H6 N2 O2
CI   COM
```

SR CA
LC STN Files: CA, CAPLUS, USPATFULL
DT.CA CAplus document type: Patent
RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); PRP (Properties); USES (Uses)
RLD.P Roles for non-specific derivatives from patents: BIOL (Biological study); USES (Uses)



Predicted Properties (PPROP)

| PROPERTY (CODE) | VALUE | CONDITION | NOTE |
|---|---|---|---|
| Bioconc. Factor (BCF) | 1.0 | pH 1 25 deg C | (1) |
| Bioconc. Factor (BCF) | 1.0 | pH 2 25 deg C | (1) |
| Bioconc. Factor (BCF) | 1.0 | pH 3 25 deg C | (1) |
| Bioconc. Factor (BCF) | 1.0 | pH 4 25 deg C | (1) |
| Bioconc. Factor (BCF) | 1.0 | pH 5 25 deg C | (1) |
| Bioconc. Factor (BCF) | 1.0 | pH 6 25 deg C | (1) |
| Bioconc. Factor (BCF) | 1.0 | pH 7 25 deg C | (1) |
| Bioconc. Factor (BCF) | 1.0 | pH 8 25 deg C | (1) |
| Bioconc. Factor (BCF) | 1.0 | pH 9 25 deg C | (1) |
| Bioconc. Factor (BCF) | 1.0 | pH 10 25 deg C | (1) |
| Boiling Point (BP) | 379.0+/-37.0 deg C | 760 Torr | (1) |
| Density (DEN) | 1.409+/-0.06 g/cm**3 | 760 Torr | (1) |
| Enthalpy of Vap. (HVAP) | 72.53+/-6.0 kJ/mol | 760 Torr | (1) |
| Flash Point (FP) | 183.0+/-26.5 deg C | | (1) |
| Freely Rotatable Bonds (FRB) | 3 | | (1) |
| H acceptors (HAC) | 4 | | (1) |
| H donors (HD) | 5 | | (1) |
| Hydrogen Donors/Acceptors Sum (HDAS) | 9 | | (1) |
| Koc (KOC) | 1.0 | pH 1 25 deg C | (1) |
| Koc (KOC) | 1.0 | pH 2 25 deg C | (1) |
| Koc (KOC) | 1.0 | pH 3 25 deg C | (1) |
| Koc (KOC) | 1.0 | pH 4 25 deg C | (1) |
| Koc (KOC) | 1.0 | pH 5 25 deg C | (1) |
| Koc (KOC) | 1.0 | pH 6 25 deg C | (1) |
| Koc (KOC) | 1.52 | pH 7 25 deg C | (1) |
| Koc (KOC) | 2.47 | pH 8 25 deg C | (1) |
| Koc (KOC) | 2.63 | pH 9 25 deg C | (1) |
| Koc (KOC) | 2.63 | pH 10 25 deg C | (1) |
| LOGD (LOGD) | -4.85 | pH 1 25 deg C | (1) |
| LOGD (LOGD) | -4.84 | pH 2 25 deg C | (1) |
| LOGD (LOGD) | -4.78 | pH 3 25 deg C | (1) |
| LOGD (LOGD) | -4.42 | pH 4 25 deg C | (1) |
| LOGD (LOGD) | -3.60 | pH 5 25 deg C | (1) |
| LOGD (LOGD) | -2.67 | pH 6 25 deg C | (1) |
| LOGD (LOGD) | -1.99 | pH 7 25 deg C | (1) |
| LOGD (LOGD) | -1.78 | pH 8 25 deg C | (1) |
| LOGD (LOGD) | -1.75 | pH 9 25 deg C | (1) |
| LOGD (LOGD) | -1.75 | pH 10 25 deg C | (1) |
| LOGP (LOGP) | -1.745+/-0.476 | 25 deg C | (1) |
| Mass Intrinsic Solubility (ISLB.MASS) | 230 g/L | 25 deg C | (1) |

| | | | |
|---|---|---|---|
| Mass Solubility (SLB.MASS) | 999.9 g/L | pH 1 25 deg C | (1) |
| Mass Solubility (SLB.MASS) | 999.9 g/L | pH 2 25 deg C | (1) |
| Mass Solubility (SLB.MASS) | 999.9 g/L | pH 3 25 deg C | (1) |
| Mass Solubility (SLB.MASS) | 999.9 g/L | pH 4 25 deg C | (1) |
| Mass Solubility (SLB.MASS) | 999.9 g/L | pH 5 25 deg C | (1) |
| Mass Solubility (SLB.MASS) | 999.9 g/L | pH 6 25 deg C | (1) |
| Mass Solubility (SLB.MASS) | 398 g/L | pH 7 25 deg C | (1) |
| Mass Solubility (SLB.MASS) | 246 g/L | pH 8 25 deg C | (1) |
| Mass Solubility (SLB.MASS) | 231 g/L | pH 9 25 deg C | (1) |
| Mass Solubility (SLB.MASS) | 231 g/L | pH 10 25 deg C | (1) |
| Mass Solubility (SLB.MASS) | 230 g/L | Unbuffered Water, pH 9.50, 25 deg C | (1) |
| Molar Intrinsic Solubility (ISLB.MOL) | 2.55 mol/L | 25 deg C | (1) |
| Molar Solubility (SLB.MOL) | 11.10 mol/L | pH 1 25 deg C | (1) |
| Molar Solubility (SLB.MOL) | 11.10 mol/L | pH 2 25 deg C | (1) |
| Molar Solubility (SLB.MOL) | 11.10 mol/L | pH 3 25 deg C | (1) |
| Molar Solubility (SLB.MOL) | 11.10 mol/L | pH 4 25 deg C | (1) |
| Molar Solubility (SLB.MOL) | 11.10 mol/L | pH 5 25 deg C | (1) |
| Molar Solubility (SLB.MOL) | 11.10 mol/L | pH 6 25 deg C | (1) |
| Molar Solubility (SLB.MOL) | 4.42 mol/L | pH 7 25 deg C | (1) |
| Molar Solubility (SLB.MOL) | 2.73 mol/L | pH 8 25 deg C | (1) |
| Molar Solubility (SLB.MOL) | 2.56 mol/L | pH 9 25 deg C | (1) |
| Molar Solubility (SLB.MOL) | 2.56 mol/L | pH 10 25 deg C | (1) |
| Molar Solubility (SLB.MOL) | 2.55 mol/L | Unbuffered Water, pH 9.50, 25 deg C | (1) |
| Molar Volume (MVOL) | 63.9+/-3.0 cm**3/mol | 20 deg C, 760 Torr | (1) |
| Molecular Weight (MW) | 90.08 | | (1) |
| PKA (PKA) | 12.12+/-0.20 | Most Acidic, 25 deg C | (1) |
| PKA (PKA) | 6.87+/-0.50 | Most Basic, 25 deg C | (1) |
| Polar Surface Area (PSA) | 89.34 A**2 | | (1) |
| Vapor Pressure (VP) | 2.67E-07 Torr | 25 deg C | (1) |

(1) Calculated using Advanced Chemistry Development (ACD/Labs) Software V8.19 ((C) 1994-2007 ACD/Labs)

See HELP PROPERTIES for information about property data sources in REGISTRY.

2 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1 Applicant

AN 142:441834 CA
TI Identification of compounds that inhibit replication of human immunodeficiency virus
IN Balzarini, Jan Maria Rene; Vahlne, Anders; Hogberg, Marita; Tong, Weimin
PA Belg.
SO U.S. Pat. Appl. Publ., 91 pp., Cont.-in-part of U.S. Ser. No. 783,053.
CODEN: USXXCO
DT Patent
LA English
IC ICM A61K031-53
ICS A61K031-513; A61K031-495; A61K031-445
NCL 514242000
CC 1-5 (Pharmacology)
Section cross-reference(s): 63
FAN.CNT 2

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|---|
| PI | US 2005096319 | A1 | 20050505 | US 2004-920831 | 20040818 |
| | US 2004180893 | A1 | 20040916 | US 2004-783053 | 20040219 |
| | WO 2006030323 | A2 | 20060323 | WO 2005-IB3755 | 20050816 |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| | RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |
| | US 2006188920 | A1 | 20060824 | US 2006-409671 | 20060424 |
| | US 2006183748 | A1 | 20060817 | US 2006-410633 | 20060425 |
| PRAI | US 2003-449494P | 20030221 | | | |
| | US 2003-493893P | 20030808 | | | |
| | US 2003-505217P | 20030922 | | | |
| | US 2004-783053 | 20040219 | | | |
| | WO 2004-IB865 | 20040219 | | | |
| | US 2004-920831 | 20040818 | | | |

AB The present invention relates to the discovery of a novel class of compds. that inhibit the replication of human immunodeficiency virus (HIV) and approaches to identify these compds. More specifically, it has been found that enzymically prepared alpha-hydroxyglycinamide and synthetically prepared alpha-hydroxyglycinamide inhibit the replication of HIV in human serum. Embodiments include methods to identify modified glycinamide compds. that inhibit HIV, methods to isolate and synthesize modified glycinamide compds., and therapeutic compns. comprising these compds.

ST replication human immunodeficiency virus hydroxyglycinamide

IT Drug delivery systems
(capsules; identification of compds. that inhibit replication of human immunodeficiency virus)

IT Drug delivery systems
(gels; identification of compds. that inhibit replication of human immunodeficiency virus)

IT Antiviral agents
Blood analysis
Drug bioavailability
Human
Human coxsackievirus B4
Human herpesvirus 1
Human herpesvirus 2
Human immunodeficiency virus 1
Human parainfluenza virus 3
Phaseolus vulgaris
Punta Toro virus
Reovirus 1
Sindbis virus
T cell (lymphocyte)
Urine analysis
Vaccinia virus
Vesicular stomatitis virus
(identification of compds. that inhibit replication of human immunodeficiency virus)

IT Drug delivery systems
(injections, i.v.; identification of compds. that inhibit replication of human immunodeficiency virus)

IT Drug delivery systems
(oral; identification of compds. that inhibit replication of human

immunodeficiency virus)

IT Drug delivery systems
(powders; identification of compds. that inhibit replication of human immunodeficiency virus)

IT Drug delivery systems
(prodrugs; identification of compds. that inhibit replication of human immunodeficiency virus)

IT Drug delivery systems
(tablets; identification of compds. that inhibit replication of human immunodeficiency virus)

IT 748135-32-2P
RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(identification of compds. that inhibit replication of human immunodeficiency virus)

IT 56-40-6, Glycine, biological studies 56-41-7, L-Alanine, biological studies 61-90-5, L-Leucine, biological studies 107-15-3, Ethylenediamine, biological studies 147-85-3, L-Proline, biological studies 328-38-1, D-Leucine 598-41-4, Glycinamide 616-29-5, 1,3-Diamino-2-hydroxypropane 687-51-4, L-Leucinamide 729-24-8 2058-58-4, D-Asparagine 2280-40-2, L-Threoninamide 2788-83-2, L-Argininamide 4540-60-7, L-Valinamide 4985-46-0, L-Tyrosinamide 5241-58-7, L-Phenylalaninamide 6250-76-6, Sarcosinamide 6720-02-1 6791-49-7, L-Serinamide 7324-05-2, L-Alaninamide 7531-52-4, L-Prolinamide 13079-20-4, DL-Leucinamide 13123-70-1, 1,4-Diamino-2-butanone 14445-54-6, L-Isoleucinamide 16748-73-5, L-Asparaginamide 16992-40-8 17193-31-6, DL-Phenylalaninamide 17756-51-3 17756-52-4 20696-57-5, L-Tryptophanamide 22356-89-4, Glycine methylamide 23645-02-5 32388-19-5, L-Lysinamide 36791-04-5, Ribavirin 49705-99-9, L-Threoninamide 54262-83-8 67934-84-3 69304-47-8, BVDU 82410-32-0, DHPG 105301-27-7 123796-46-3, Aziridinethione 126675-52-3 139138-91-3 141497-12-3 748135-33-3 748135-34-4 748135-35-5 748135-40-2 757242-72-1 850635-17-5 850635-18-6
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(identification of compds. that inhibit replication of human immunodeficiency virus)

IT 475106-70-8P
RL: PRP (Properties); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(identification of compds. that inhibit replication of human immunodeficiency virus)

IT 132629-33-5P 150749-04-5P 150749-05-6P 150749-06-7P 150749-11-4P 748135-41-3P 748135-42-4P
RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation)
(identification of compds. that inhibit replication of human immunodeficiency virus)

IT 563-96-2, Glyoxylic acid monohydrate 4248-19-5, tert-Butyl carbamate 19757-97-2 84418-43-9
RL: RCT (Reactant); RACT (Reactant or reagent)
(identification of compds. that inhibit replication of human immunodeficiency virus)

IT 96-35-5P 150749-03-4P 748135-37-7P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(identification of compds. that inhibit replication of human immunodeficiency virus)

IT 850844-65-4 850844-66-5 850844-67-6 850844-68-7 850844-69-8 850844-70-1 850844-71-2 850844-72-3 850844-73-4 850844-74-5 850844-75-6 850844-76-7 850844-77-8 850844-78-9 850844-79-0 850844-80-3 850844-81-4
RL: BSU (Biological study, unclassified); BIOL (Biological study)

(nucleotide sequence; identification of compds. that inhibit replication of human immunodeficiency virus)
IT 850845-98-6 850845-99-7
RL: PRP (Properties)
(unclaimed nucleotide sequence; identification of compds. that inhibit replication of human immunodeficiency virus)
IT 850845-96-4 850845-97-5
RL: PRP (Properties)
(unclaimed protein sequence; identification of compds. that inhibit replication of human immunodeficiency virus)

REFERENCE 2

AN 141:218926 CA
TI Glycinamide derivatives for inhibiting HIV replication
IN Balzarini, Jan Maria Rene; Vahlne, Anders; Hogberg, Marita; Tong, Weimin
PA Tripep AB, Swed.
SO PCT Int. Appl., 92 pp.
CODEN: PIXXD2
DT Patent
LA English
IC ICM A61K031-164
ICS A61K038-06; A61P031-18
CC 1-5 (Pharmacology)
Section cross-reference(s): 34, 63
FAN.CNT 2

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| PI WO 2004073703 | A1 | 20040902 | WO 2004-IB865 | 20040219 |
| WO 2004073703 | B1 | 20041104 | | |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI | | | | |
| RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| AU 2004212786 | A1 | 20040902 | AU 2004-212786 | 20040219 |
| CA 2515679 | A1 | 20040902 | CA 2004-2515679 | 20040219 |
| EP 1603546 | A1 | 20051214 | EP 2004-712638 | 20040219 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK | | | | |
| CN 1777414 | A | 20060524 | CN 2004-80010780 | 20040219 |
| JP 2006518373 | T | 20060810 | JP 2006-502493 | 20040219 |
| US 2006183748 | A1 | 20060817 | US 2006-410633 | 20060425 |

PRAI US 2003-449494P 20030221
US 2003-493893P 20030808
US 2003-505217P 20030922
US 2004-783053 20040219
WO 2004-IB865 20040219
US 2004-920831 20040818

AB The invention relates to the discovery of a novel class of compds. that inhibit the replication of human immunodeficiency virus (HIV), as well as approaches to identify these compds. More specifically, it has been found that enzymically prepared α-hydroxyglycinamide and synthetically prepared α-hydroxyglycinamide inhibit the replication of HIV in human serum. Embodiments include methods to identify modified glycinamide compds. that inhibit HIV, methods to isolate and synthesize modified glycinamide compds., and therapeutic compns. comprising these compds.
ST HIV replication inhibitor glycinamide deriv prepn; hydroxyglycinamide HIV replication inhibitor
IT Cell
(extract, incubation with; glycinamide derivs. for inhibiting HIV

replication)
IT AIDS (disease)
Anti-AIDS agents
Antiviral agents
Cation exchange chromatography
Drug delivery systems
Drug screening
Human
Human coxsackievirus B4
Human herpesvirus 1
Human herpesvirus 2
Human immunodeficiency virus
Human immunodeficiency virus 1
Human immunodeficiency virus 2
Human parainfluenza virus 3
Lymphocyte
Punta Toro virus
Reovirus 1
Respiratory syncytial virus
Sindbis virus
T cell (lymphocyte)
Vaccinia virus
Vesicular stomatitis virus
(glycinamide derivs. for inhibiting HIV replication)
IT Mus
(incubation with serum of; glycinamide derivs. for inhibiting HIV replication)
IT Bos taurus
Canis familiaris
Equus caballus
Felis catus
Sus scrofa domestica
(incubation with serum or plasma of; glycinamide derivs. for inhibiting HIV replication)
IT Ape
Monkey
(incubation with simian serum or plasma; glycinamide derivs. for inhibiting HIV replication)
IT Blood plasma
Blood serum
(incubation with; glycinamide derivs. for inhibiting HIV replication)
IT 54249-88-6
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(glycinamide derivs. for inhibiting HIV replication)
IT 748135-38-8
RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(glycinamide derivs. for inhibiting HIV replication)
IT 748803-81-8, Partisphere SCX
RL: MSC (Miscellaneous)
(glycinamide derivs. for inhibiting HIV replication)
IT 56-40-6, Glycine, biological studies 56-41-7, L-Alanine, biological studies 61-90-5, L-Leucine, biological studies 107-15-3, Ethylene diamine, biological studies 147-85-3, L-Proline, biological studies 328-38-1, D-Leucine 515-94-6 616-29-5, 1,3-Diamino-2-hydroxypropane 687-51-4, L-Leucinamide 729-24-8 2058-58-4, D-Asparagine 2788-83-2, L-Argininamide 4510-08-1, L-Methioninamide 4540-60-7, L-Valinamide 4985-46-0, L-Tyrosinamide 5241-58-7, L-Phenylalaninamide 6250-76-6, Sarcosinamide 6720-02-1, DL-Tryptophanamide 6791-49-7, L-Serinamide 7324-05-2, L-Alaninamide 7531-52-4, L-Prolinamide 13079-20-4, DL-Leucinamide 13123-70-1, 1,4-Diamino-2-butanone 14445-54-6, L-Isoleucinamide 16748-73-5, L-Asparaginamide 17193-31-6, DL-Phenylalaninamide 20696-57-5, L-Tryptophanamide 22356-89-4, Glycine methylamide 23645-02-5, 1,3-Diaminoacetone 32388-19-5, L-Lysinamide

49705-99-9, L-Threoninamide 105301-27-7 123796-46-3, Aziridinethione
126675-52-3 136259-22-8
RL: PAC (Pharmacological activity); BIOL (Biological study)
(glycinamide derivs. for inhibiting HIV replication)

IT 598-41-4D, Glycinamide, derivs. 67934-84-3 748135-32-2 748135-32-2D,
derivs. 748135-33-3 748135-34-4 748135-35-5 748135-36-6
748135-39-9 748135-40-2
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
(glycinamide derivs. for inhibiting HIV replication)

IT 64-17-5, Ethanol, reactions 67-56-1, Methanol, reactions 67-63-0,
Isopropyl alcohol, reactions 563-96-2 621-84-1, Benzyl carbamate
4248-19-5, tert-Butyl carbamate 7647-01-0, Hydrochloric acid, reactions
7664-41-7, Ammonia, reactions 84418-43-9
RL: RCT (Reactant); RACT (Reactant or reagent)
(glycinamide derivs. for inhibiting HIV replication)

IT 4746-62-7P 19757-97-2P 132629-33-5P 150749-03-4P 150749-04-5P
475106-70-8P 748135-37-7P 748135-41-3P 748135-42-4P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(glycinamide derivs. for inhibiting HIV replication)

IT 150749-05-6P 150749-06-7P 150749-09-0P 150749-10-3P 150749-11-4P,
α-Hydroxyglycinamide hydrochloride 150749-12-5P
RL: SPN (Synthetic preparation); PREP (Preparation)
(glycinamide derivs. for inhibiting HIV replication)

=>